Lifecore dispute panel update
This article was originally published in Clinica
Executive Summary
Information is emerging about the reason for the indefinite postponement of the FDA's first dispute resolution advisory panel, which happened just a few days before the meeting which was scheduled for June 4 (see Clinica No 957, p 1). Lifecore Biomedical had requested the meeting to challenge the FDA's decision not to approve its Intergel adhesion prevention barrier solution.